<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616265</url>
  </required_header>
  <id_info>
    <org_study_id>Prot-740</org_study_id>
    <secondary_id>Prot-740 SEPAR</secondary_id>
    <secondary_id>SEPAR-90</secondary_id>
    <nct_id>NCT00616265</nct_id>
  </id_info>
  <brief_title>Effect of Continuous Positive Airway Pressure (CPAP) Treatment in the Control of Refractory Hypertension</brief_title>
  <official_title>Effect of CPAP Treatment in the Control of Refractory Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sociedad Española de Neumología y Cirugía Torácica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The working hypothesis for the present study is that treatment with CPAP in patients with an&#xD;
      sleep apnea (IAH&gt;15) and AHT-r is capable of producing significant reductions in&#xD;
      blood-pressure levels.&#xD;
&#xD;
      This hypothesis is supported by four proven findings:&#xD;
&#xD;
        1. -sleep apnea is an independent risk factor for arterial hypertension (1).&#xD;
&#xD;
        2. -The greater the number of RSD, the greater the loss of control over blood-pressure&#xD;
           levels (1).&#xD;
&#xD;
        3. -The prevalence of sleep apnea in patients with AHT refractory to treatment is very high&#xD;
           (11,12).&#xD;
&#xD;
        4. -Treatment of patients with sleep apnea and AHT-r with CPAP succeeds in significantly&#xD;
           reducing blood-pressure levels in the only (small-scale) studies undertaken to date&#xD;
           (14,15).&#xD;
&#xD;
      4. OBJECTIVES&#xD;
&#xD;
      Main objective:&#xD;
&#xD;
      To evaluate the effect of treatment with CPAP on blood-pressure levels in patients with AHT&#xD;
      refractory to medical treatment.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To evaluate the effect of treatment with CPAP on the various elements assessed in BP&#xD;
           (systolic/diastolic; daytime/nighttime, etc) and the circadian profile&#xD;
           (dipper/non-dipper/raiser patterns; variability and homogeneity of blood-pressure&#xD;
           levels, etc) obtained during a 24-hour out-patient study (AMPA).&#xD;
&#xD;
        -  To analyze the related variables or subgroups of patients most affected by treatment&#xD;
           with CPAP.&#xD;
&#xD;
        -  To evaluate the effect of CPAP on the levels of some of the biological variables&#xD;
           involved in the pathogenesis of AHT-r (renin, angiotensin, aldosterone, atrial&#xD;
           natriuretic factor, etc).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE. To evaluate the effect of continuous positive airway pressure (CPAP) treatment on&#xD;
      the blood-pressure (BP) levels of patients with refractory arterial hypertension (AHT-r).&#xD;
&#xD;
      METHODS: Multicenter randomized study with parallel groups and blind final evaluation.&#xD;
&#xD;
      Patients will be recruited from AHT, nephrology or internal medicine outpatient clinics and&#xD;
      will satisfy the criteria for AHT-r (patients requiring 3 anti-AHT drugs at recommended doses&#xD;
      to maintain their blood-pressure levels within AMPA [24-hours ambulatory monitoring of blood&#xD;
      pressure values) excluding those forms of secondary AHT and those patients with&#xD;
      incapacitating hypersomnia that need immediate treatment. In all, 210 patients will be&#xD;
      included (105 per arm for intention to treat analysis) in accordance with the calculation of&#xD;
      the sample size needed including drop-outs to evaluate a clinically significant minimum drop&#xD;
      of 4-5 mmHg in the mean BP and the number of centers (21 centers; 10 patients per center).&#xD;
      They will all be subjected to a complete clinical history, an AMPA study, a blood test (with&#xD;
      serum retained for a later determination of biological mediators) and a sleep study. Those&#xD;
      patients with an AHI&gt;15 will be randomized to receive CPAP vs habitual control. The treatment&#xD;
      will last 3 months. The same variables that were measured before the randomization will be&#xD;
      analyzed again for the purposes of comparison. The comparison of results will be undertaken&#xD;
      on the basis of an intention-to-treat and per-protocol analyses based on adherence to CPAP&#xD;
      treatment at different cutoff of hours /day by means of an ANOVA two-way analysis (one of&#xD;
      them being time).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on blood pressure levels</measure>
    <time_frame>Before and six months after CPAP treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on night blood pressure pattern</measure>
    <time_frame>Befor and six month after CPAP treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group B. Only Usual Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: Cpap treatment plus Usual control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>Pressure device on airway to maintain it open</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Continuous positive airway pressure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18-75 with a diagnosis of primary AHT-r and an AHI ≥15.&#xD;
&#xD;
          2. Signature indicating informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those patients with, in the opinion of the researcher, incapacitating hypersomnia will&#xD;
             be excluded (to avoid the ethical problems associated with not treating a symptomatic&#xD;
             sleep apnea patient).&#xD;
&#xD;
          2. Patients with risky professions or work involving dangerous goods.&#xD;
&#xD;
          3. Pregnancy.&#xD;
&#xD;
          4. The regular use of psychotropic drugs that could significantly modify the results of&#xD;
             the sleep studies, or previous alcoholism (more than 100 gr of alcohol/day).&#xD;
&#xD;
          5. Patients previously treated with CPAP.&#xD;
&#xD;
          6. Record of poor compliance with anti-hypertensive treatment.&#xD;
&#xD;
          7. AHT secondary to cardiac insufficiency, valvulopathy, renal or endocrinological&#xD;
             causes, cor pulmonale or the consumption of oral corticoids, or any other known cause.&#xD;
&#xD;
          8. Patients who have suffered from a cardiovascular event in the month prior to inclusion&#xD;
             in the study, or patients who were unstable at the time of their inclusion in the&#xD;
             study.&#xD;
&#xD;
          9. Known renal insufficiency with a concentration of creatinine greater than 1.5 mg/dl&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Angel Martínez-Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sociedad Española de Neumología y Cirugía Torácica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital of Requena</name>
      <address>
        <city>Valencia</city>
        <zip>42340</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>February 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>February 28, 2012</last_update_submitted>
  <last_update_submitted_qc>February 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sociedad Española de Neumología y Cirugía Torácica</investigator_affiliation>
    <investigator_full_name>Miguel angel Martinez Garcia</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Sleep apnea</keyword>
  <keyword>Refractory Hypertension</keyword>
  <keyword>Difficult-to-treat hypertension</keyword>
  <keyword>CPAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

